# BD Diagnostics BD MAX ™ StaphSR Assay PreMarket Notification

510(k) Summary

November 19, 2013

# BD Diagnostics BD MAX ™ StaphSR

# Submitted by:

GeneOhm Sciences Canada Inc. (BD Diagnostics)   
2555 Boul. Parc-Technologique   
Quebec (Quebec), Canada   
G1P 4S5

# Contact:

Patricia Dionne, Ph.D.

# Device:

NOV 2 6 2013

510(k) Number:

K132822

Trade Name:

BD MAX™ StaphSR

Common Name:

Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus detection assay

Type of Test:

Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus Qualitative Nucleic Acid Amplification Test from nasal swab specimens

# Classification:

II

Regulation Name:

Antimicrobial susceptibility test powder

Regulation Number:

866.1640

Product Code:

NQX, 0OI

# Panel:

Microbiology (83)

Predicate Devices: BD MAX™ MRSA and BD GeneOhm™ StaphSR Assay

Predicate $5 1 0 ( k )$ Numbers: K120138 and K071026

# Intended Use:

The BD MAX™ StaphSR assay performed on the BD MAX™ System is an automated qualitative in vitro diagnostic test for the direct detection and differentiation of Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization. The test utilizes realtime polymerase chain reaction (PCR) for the amplification of MRSA/SA DNA and fluorogenic target-specific hybridization probes for the detection of the amplified DNA. The BD MAX ™ StaphSR assay is intended to aid in the prevention and control of MRSA and SA infections in healthcare settings. It is not intended to diagnose MRSA or SA infections nor guide or monitor treatment for MRSA/SA infections. A negative result does

# BD Diagnostics BD MAX ™ StaphSR Assay PreMarket Notification

not preclude nasal colonization. Concomitant cultures are necessary to recover organisms for epidemiological typing or for further susceptibility testing.

# Indication for Use:

The BD MAX ™ StaphSR assay performed on the BD MAX™ System is an automated qualitative in vitro diagnostic test for the direct detection and differentiation of Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization. The test utilizes realtime polymerase chain reaction (PCR) for the amplification of MRSA/SA DNA and fluorogenic target-specific hybridization probes for the detection of the amplified DNA. The BD MAX™ StaphSR assay is intended to aid in the prevention and control of MRSA and SA infections in healthcare settings. It is not intended to diagnose MRSA or SA infections nor guide or monitor treatment for MRSA/SA infections. A negative result does not preclude nasal colonization. Concomitant cultures are necessary to recover organisms for epidemiological typing or for further susceptibility testing.

Special Conditions for Use Statement:

For prescription use

Special Instrument Requirements:

The BD MAX™ System

# Device Description:

The BD MAX™M System and the BD MAX™M StaphSR assay are comprised of an instrument with associated hardware and accessories, disposable microfluidic cartridges, master mixes, unitized reagent strips, extraction reagents, and sample buffer tubes. The instrument automates sample preparation including target lysis, DNA extraction and concentration, reagent rehydration, and target nucleic acid amplification and detection using real-time PCR. The assay includes a Sample Processing Control (SPC) that is present in the Extraction Tube. The SPC monitors DNA extraction steps, thermal cycling steps, reagent integrity and the presence of inhibitory substances. The BD MAX ™m System software automatically interprets test results. A test result may be called as [SA NEG, MRSA NEG (negative)]. [SA POS, MRSA POS (MRSA positive)], [SA POS, MRSA NEG (SA positive)] or [SA UNR, MRSA UNR (Unresolved)] based on the amplification status of the target and of the Sample Processing Control. IND (Indeterminate) or INC (Incomplete) results are due to BD MAX ™ System failure.

# Test Principle:

The BD MAX ™ StaphSR assay performed on the BD MAX™ System is an automated in vitro diagnostic test for the direct, qualitative detection and differentiation of the Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization.

A nasal specimen is collected and transported to the laboratory using the recommended swab. The swab is placed in a BD MAX™ StaphSR Sample Buffer Tube. The Sample

# BD Diagnostics BD MAX ™ StaphSR Assay PreMarket Notification

Buffer Tube is closed with a septum cap and vortexed. A worklist is created and the Sample Buffer Tube, the BD MAX ™ StaphSR unitized reagent strip and the BD MAX™ PCR Cartridge are loaded onto the BD MAX ™ System.

Following enzymatic cell lysis, the released nucleic acids are captured on magnetic beads. The beads, with the bound nucleic acids, are washed using Wash Buffer and the nucleic acids are eluted by heat in Elution Buffer. Eluted DNA is neutralized using Neutralization Buffer and transferred to a Master Mix to rehydrate PCR reagents. After reconstitution, the BD MAX™ System dispenses a fixed volume of PCR-ready solution containing extracted nucleic acids into the BD MAX ™ PCR Cartridge. Microvalves in the BD MAX ™M PCR Cartridge are sealed by the system prior to initiating PCR to contain the amplification mixture, thus preventing evaporation and contamination.

The amplified DNA targets are detected using hydrolysis (TaqMan®) probes labeled at one end with a fluorescent reporter dye (fluorophore) and at the other end with a quencher moiety. Probes labeled with different fluorophores are used to detect a specific amplicon in the SCCmec right-extremity junction (MREJ), the genes for methicillin resistance mecA and mecC, the nuc gene encoding a thermostable nuclease of S. aureus and SPC amplicons in four different optical channels of the BD MAX™ System: MREJ amplicons are detected in the FAM channel, mecA and mecC amplicons are detected in the ROX channel, nuc amplicons are detected in the VIC channel and SPC amplicons are detected in the Cy5.5 channel. When the probes are in their native state, the fluorescence of the fluorophore is quenched due to its proximity to the quencher. However, in the presence of target DNA, the probes hybridize to their complementary sequences and are hydrolyzed by the 5'-3' exonuclease activity of the DNA polymerase as it synthesizes the nascent strand along the DNA template. As a result, the fluorophores are separated from the quencher molecules and fluorescence is emitted. The amount of fluorescence detected in the four optical channels used for the BD MAX ™ StaphSR assay is directly proportional to the quantity of the corresponding probe that is hydrolyzed. The BD MAX ™ System measures these signals at the end of each amplification cycle, and interprets the data to provide a result.

# Substantial Equivalence:

Table 1 shows the similarities and differences between the BD MAX™ StaphSR assay and the predicate devices.

# BD Diagnostics BD MAX ™ StaphSR Assay PreMarket Notification

Table 1: Substantial Equivalence Information   

<table><tr><td rowspan=2 colspan=1>ITEM</td><td rowspan=1 colspan=1>DEVICE</td><td rowspan=1 colspan=2>PREDICATE</td></tr><tr><td rowspan=1 colspan=1>BD MAX™ StaphSR(K132822)</td><td rowspan=1 colspan=1>&quot;BD GeneOhim StaphSRAssay (K071026)</td><td rowspan=1 colspan=1>BD MAX MRSA Assay(K120138)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The BD MAX™ StaphSR assayperformed on the BD MAX TSystem is an automatedqualitative in vitro diagnostic testfor the direct detection anddifferentiation of Staphylococcusaureus (SA) and methicillin-resistant Staphylococcus aureus(MRSA) DNÁ from nasal swabsin patients at risk for nasalcolonization. The test utilizesreal-time polymerase chainreaction (PCR) for theamplification of MRSA/SA DNAand fluorogenic target-specifichybridization probes for thedetection of the amplified DNA.The BD MAX™ StaphSR assayis intended to aid in theprevention and control of MRSAand SA infections in healthcaresettings. It is not intended todiagnose MRSA or SA infectionsnor guide or monitor treatmentfor MRSA/SA infections. Anegative result does notpreclude nasal colonization.Concomitant cultures arenecessary to recover organismsfor epidemiological typing or forfurther susceptibility testing.</td><td rowspan=1 colspan=1>The BD GeneOhm ™ StaphSRAssay is a qualitative in vitrodiagnostic test for the rapiddetection of Staphylococcusaureus (SA) and methicillin-resistant Staphylococcusaureus (MRA) directly frompositive blood culture. Theassay utilizes polymerasechain reaction (PCR) for theamplification of specific targetsand fluorogenic target-specifichybridization probes for thereal-time detection of theamplified DNA. The assay isperformed on Gram positivecocci, identified by Gram stain,from positive blood cultures.The BD GeneOhm ™ StaphSRAssay is not intended tomonitor treatment forMRSA/SA infections.Subculturing of positive bloodcultures is necessary forfurther susceptibility testing.</td><td rowspan=1 colspan=1>The BD MAX ™ MRSA AsSayperformed on the BD MAX™System is an automatedqualitative in vitro diagnostictest for the direct detection ofMethicillin-resistantStaphylococcus aureus (MRSA)DNA from nasal swabs inpatients at risk for nasalcolonization. The test utilizesreal-time polymerase chainreaction (PCR) for theamplification of MRSA DNA andfluorogenic target-specifichybridization probes for thedetection of the amplified DNA.The BD MAX ™ MRSA Assay isintended to aid in the preventionand control of MRSA infectionsin healthcare settings. It is notintended to diagnose, guide ormonitor MRSA infections. Anegative result does notpreclude nasal colonization.Concomitant cultures arenecessary to recover organismsfor epidemiological typing or forfurther susceptibility testing.</td></tr><tr><td rowspan=1 colspan=1>Specimen type</td><td rowspan=1 colspan=1>Nasal swabs</td><td rowspan=1 colspan=1>Positive blood culture</td><td rowspan=1 colspan=1>Nasal swabs</td></tr><tr><td rowspan=1 colspan=1>Assay Format</td><td rowspan=1 colspan=1>Amplification: PCRDetection: Fluorogenic target-specific hybridization</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Mode of Detectionfor MethicillinResistance inS.aureus</td><td rowspan=1 colspan=1>Presence of SCCmec cassetteat orfX junction and mecA ormecC genes</td><td rowspan=1 colspan=1>Presence of SCCmec cassetteat orfX junction (specific to S.aureus)</td><td rowspan=1 colspan=1>Presence of SCCmec cassetteat orfX junction (specific to S.aureus)</td></tr><tr><td rowspan=1 colspan=1>Mode of Detectionfor SA</td><td rowspan=1 colspan=1>Presence of nuc gene specificfor SA</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>Interpretation ofTest Results</td><td rowspan=1 colspan=1>Automated (Diagnostic softwareof BD MAX System)</td><td rowspan=1 colspan=1>Automated (Diagnosticsoftware of SmartCyclerSystem)</td><td rowspan=1 colspan=1>Automated (Diagnostic software BD MAX™ System)</td></tr><tr><td rowspan=1 colspan=1>Analysis Platform</td><td rowspan=1 colspan=1>BD MAX ™ System</td><td rowspan=1 colspan=1>SmartCycler® System</td><td rowspan=1 colspan=1>BD MAX™ System</td></tr><tr><td rowspan=1 colspan=1>PCR SamplePreparation</td><td rowspan=1 colspan=1>Automated by the BD MAX ™System</td><td rowspan=1 colspan=1>Manual</td><td rowspan=1 colspan=1>Automated by the BD MAX ™System</td></tr><tr><td rowspan=1 colspan=1>Detection Probes</td><td rowspan=1 colspan=1>TaqMan® Probe</td><td rowspan=1 colspan=1>Molecular Beacon Probe</td><td rowspan=1 colspan=1>TaqMan® Probe</td></tr></table>

# BD Diagnostics BD MAX ™ StaphSR Assay PreMarket Notification

<table><tr><td rowspan=2 colspan=1>ITEM</td><td rowspan=1 colspan=1>DEVICE</td><td rowspan=1 colspan=2>PREDICATE</td></tr><tr><td rowspan=1 colspan=1>BD MAX™ StaphSR(K132822)</td><td rowspan=1 colspan=1>BD GeneOhm StaphSR.Assay (K071026)</td><td rowspan=1 colspan=1>BD MAX MRSA Assay.(K120138)</td></tr><tr><td rowspan=1 colspan=1>Assay Controls</td><td rowspan=1 colspan=1>Specimen Processing Control(SPC)</td><td rowspan=1 colspan=1>Positive PCR control (DNAfrom S.aureus ATCC 43300).Negative control (DNA fromS.epidermidis ATCC 14990).Internal Control</td><td rowspan=1 colspan=1>Specimen Processing Control(SPC)</td></tr></table>

# Analytical Performance:

# Precision

Within-laboratory precision was evaluated for the BD MAX ™ StaphSR assay at one (1) site. The Precision panel consisted of 4 sample categories near the LoD. Each specimen contained simulated nasal matrix. MRSA and MSSA strains were tested as follows:

Moderate Positive (MP) MRSA (MREJ Type ii): $\geq 2$ and $\le 5 x$ LOD   
Low Positive (LP) MRSA (MREJ Type ii): ≥ 1 and $\yen 2x$ LoD   
Low Positive (LP) MRSA (MREJ Type vii): ≥ 1 and $< 2 \times$ LoD   
Low Positive (LP) MSSA: ≥ 1 and $< 2 x$ LoD   
High Negative (HN) MRSA (MREJ Type ii): $< 1 \times$ LoD   
High Negative (HN) MSSA: $\leq 1 \times$ LoD   
True negative (TN): Negative specimens (no target)

Testing was performed in duplicate, over 12 days, with 2 runs per day, by 2 different technologists. Precision study results for TN, MP, LP, and HN MRSA samples demonstrated $100 \%$ . $100 \%$ . $9 7 . 9 \%$ ,and $2 7 . 1 \%$ agreement, respectively. Precision study results for LP and HN MSSA samples demonstrated $100 \%$ and $56 . 2 \%$ agreement, respectively.

# Reproducibility

The reproducibility study was performed using the same sample categories as defined above for the Precision Study.

Samples in each category were tested in triplicate, on 5 distinct days, wherein each day 2 panels were tested by 2 different technologists, at 3 clinical sites using 1 lot of reagents (Site-to-Site). One (1) of these clinical sites participated in an extended study where 2 additional lots of reagents were tested (Lot-to-Lot). Results are shown for each sample category with the data from both MRSA strains pooled and MSSA strains.

For Site-to-Site Reproducibility, the overall percent agreement was $100 \%$ for MRSA MP and TN categories; $9 6 . 7 \%$ and $9 7 . 8 \%$ for MRSA LP and MSSA LP, respectively; and E $3 6 . 7 \%$ and $30 . 0 \%$ for MRSA HN and MSSA HN, respectively (Table 2).

# BD Diagnostics BD MAX ™ StaphSR Assay PreMarket Notification

Table 2. Site-To-Site Reproducibility Study Results Using One Lot of the BD MAX™ StaphSR Assay   

<table><tr><td rowspan=3 colspan=1>Category</td><td rowspan=1 colspan=6>SITE</td><td rowspan=3 colspan=2>Overall PercentAgreement</td></tr><tr><td rowspan=1 colspan=2>Site 1</td><td rowspan=1 colspan=2>Site 2</td><td rowspan=1 colspan=2>Site 3</td></tr><tr><td rowspan=1 colspan=1>PercentAgreement</td><td rowspan=1 colspan=1>Count</td><td rowspan=1 colspan=1>PercentAgreement</td><td rowspan=1 colspan=1>Count</td><td rowspan=1 colspan=1>PercentAgreement</td><td rowspan=1 colspan=1>Count</td></tr><tr><td rowspan=1 colspan=1>HN&#x27; MSSA</td><td rowspan=1 colspan=1>16.7%</td><td rowspan=1 colspan=1>5/30</td><td rowspan=1 colspan=1>23.3%</td><td rowspan=1 colspan=1>7/30</td><td rowspan=1 colspan=1>50.0%</td><td rowspan=1 colspan=1>15/30</td><td rowspan=1 colspan=1>30.0%</td><td rowspan=1 colspan=1>(21.5%, 40.1%)²2</td></tr><tr><td rowspan=1 colspan=1>HN MRSA</td><td rowspan=1 colspan=1>40.0%</td><td rowspan=1 colspan=1>12/30</td><td rowspan=1 colspan=1>26.7%</td><td rowspan=1 colspan=1>8/30</td><td rowspan=1 colspan=1>43.3%</td><td rowspan=1 colspan=1>13/30</td><td rowspan=1 colspan=1>36.7%</td><td rowspan=1 colspan=1>(27.4%, 47.0%)</td></tr><tr><td rowspan=1 colspan=1>LP MSSA</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>97.8%</td><td rowspan=1 colspan=1>(92.3%, 99.4%)</td></tr><tr><td rowspan=1 colspan=1>LP MRSA</td><td rowspan=1 colspan=1>95.0%</td><td rowspan=1 colspan=1>57/60</td><td rowspan=1 colspan=1>98.3%</td><td rowspan=1 colspan=1>59/60</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>58/60</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>(92.9%, 98.5%)</td></tr><tr><td rowspan=1 colspan=1>MP MRSA</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>(95.9%, 100.0%)</td></tr><tr><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>(95.9%, 100.0%)</td></tr></table>

1Percent Agreement correlates to the percent of negative results. 2Confidence Interval

For Lot-to-Lot Reproducibility, the overall percent agreement was $100 \%$ for MRSA MP and TN; $9 6 . 7 \%$ for MRSA LP and MSSA LP; $40 . 0 \%$ and $4 4 . 4 \%$ for MRSA HN and MSSA HN, respectively (Table 3).

Table 3. Lot-To-Lot Reproducibility Study Results using Three Lots of the BD MAX™ StaphSR Assay   

<table><tr><td rowspan=3 colspan=1>Category</td><td rowspan=1 colspan=6>LOT</td><td rowspan=3 colspan=2>Overall PercentAgreement</td></tr><tr><td rowspan=1 colspan=2>Lot 1</td><td rowspan=1 colspan=2>Lot 2</td><td rowspan=1 colspan=2>Lot 3</td></tr><tr><td rowspan=1 colspan=1>PercentAgreement</td><td rowspan=1 colspan=1>Count</td><td rowspan=1 colspan=1>PercentAgreement</td><td rowspan=1 colspan=1>Count</td><td rowspan=1 colspan=1>PercentAgreement</td><td rowspan=1 colspan=1>Count</td></tr><tr><td rowspan=1 colspan=1>HN&#x27; MSSA</td><td rowspan=1 colspan=1>50.0%</td><td rowspan=1 colspan=1>15/30</td><td rowspan=1 colspan=1>36.7%</td><td rowspan=1 colspan=1>11/30</td><td rowspan=1 colspan=1>46.7%</td><td rowspan=1 colspan=1>14/30</td><td rowspan=1 colspan=1>44.4%</td><td rowspan=1 colspan=1>(34.6%, 54.7%)²</td></tr><tr><td rowspan=1 colspan=1>HN MRSA</td><td rowspan=1 colspan=1>43.3%</td><td rowspan=1 colspan=1>13/30</td><td rowspan=1 colspan=1>43.3%</td><td rowspan=1 colspan=1>13/30</td><td rowspan=1 colspan=1>33.3%</td><td rowspan=1 colspan=1>10/30</td><td rowspan=1 colspan=1>40.0%</td><td rowspan=1 colspan=1>(30.5%, 50.3%)</td></tr><tr><td rowspan=1 colspan=1>LP MSSA</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>93.3%</td><td rowspan=1 colspan=1>28/30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>(90.7%, 98.9%)</td></tr><tr><td rowspan=1 colspan=1>LP MRSA</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>58/60</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>58/60</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>58/60</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>(92.9%, 98.5%)</td></tr><tr><td rowspan=1 colspan=1>MP MRSA</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>(95.9%, 100.0%)</td></tr><tr><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>(95.9%, 100.0%)</td></tr></table>

1Percent Agreement correlates to the percent of negative results. 2Confidence Interval

Site-to-Site and Lot-to-Lot Reproducibility performance was acceptable for the LP, MP, and TN sample categories. No specific acceptance criteria was defined for the high negative sample category.

# BD Diagnostics BD MAX™ StaphSR Assay PreMarket Notification

Second Derivative Peak Abscissa (SDPA), an underlying numerical value used to determine a final assay result, was selected as an additional means of assessing assay reproducibility. Overall mean SDPA values with variance components (SD and $\% C V )$ are shown in Table 4.

Table 4. Site-to-Site and Lot-to-Lot Reproducibility Study Underlying Numerical SDPA Overall Results   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Site-to-Site</td><td rowspan=1 colspan=3>Lot-to-Lot</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>HN MRSA</td><td rowspan=1 colspan=1>LP MRSA</td><td rowspan=1 colspan=1>MP MRSA</td><td rowspan=1 colspan=1>HN MRSA</td><td rowspan=1 colspan=1>LP MRSA</td><td rowspan=1 colspan=1>MP MRSA</td></tr><tr><td rowspan=4 colspan=1>MREJ&#x27; (MREJtypes pooled.FAM Channel)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>174</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>174</td><td rowspan=1 colspan=1>90</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>33.5</td><td rowspan=1 colspan=1>31.1</td><td rowspan=1 colspan=1>30.7</td><td rowspan=1 colspan=1>33.4</td><td rowspan=1 colspan=1>31.0</td><td rowspan=1 colspan=1>30.8</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.72</td><td rowspan=1 colspan=1>1.05</td><td rowspan=1 colspan=1>0.71</td><td rowspan=1 colspan=1>0.72</td><td rowspan=1 colspan=1>0.94</td><td rowspan=1 colspan=1>0.37</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>1.2%</td></tr><tr><td rowspan=4 colspan=1>mecA or mecC2(MREJ typespooled, ROXChannel)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>174</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>174</td><td rowspan=1 colspan=1>90</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>35.1</td><td rowspan=1 colspan=1>31.8</td><td rowspan=1 colspan=1>31.1</td><td rowspan=1 colspan=1>35.0</td><td rowspan=1 colspan=1>31.7</td><td rowspan=1 colspan=1>31.1</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.16</td><td rowspan=1 colspan=1>1.42</td><td rowspan=1 colspan=1>0.78</td><td rowspan=1 colspan=1>1.15</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>0.54</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>1.7%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>HN MREJType ii</td><td rowspan=1 colspan=1>HN MSSA</td><td rowspan=1 colspan=1>LP MSSA</td><td rowspan=1 colspan=1>HN MREJType il</td><td rowspan=1 colspan=1>HN MSSA</td><td rowspan=1 colspan=1>LP MSSA</td></tr><tr><td rowspan=4 colspan=1>nuc^3(VIC Channel)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>87</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>34.9</td><td rowspan=1 colspan=1>34.8</td><td rowspan=1 colspan=1>32.0</td><td rowspan=1 colspan=1>35.2</td><td rowspan=1 colspan=1>34.8</td><td rowspan=1 colspan=1>32.0</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.78</td><td rowspan=1 colspan=1>1.69</td><td rowspan=1 colspan=1>1.12</td><td rowspan=1 colspan=1>1.85</td><td rowspan=1 colspan=1>1.57</td><td rowspan=1 colspan=1>0.78</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>4.9%</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>2.4%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>HN MREJType il</td><td rowspan=1 colspan=1>HN MSSA</td><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>HN MREJType ii</td><td rowspan=1 colspan=1>HN MSSA</td><td rowspan=1 colspan=1>TN</td></tr><tr><td rowspan=4 colspan=1>SPC4(Cy5.5 Channel)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>90</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>30.0</td><td rowspan=1 colspan=1>30.3</td><td rowspan=1 colspan=1>30.2</td><td rowspan=1 colspan=1>29.9</td><td rowspan=1 colspan=1>30.0</td><td rowspan=1 colspan=1>30.0</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.79</td><td rowspan=1 colspan=1>0.68</td><td rowspan=1 colspan=1>0.63</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>0.45</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>1.5%</td></tr></table>

Values shown are those obtained for the MREJ target in the samples that gave a SA POS, MRSA POS result on  oai eget  hepsha av SA OSRS OS ul 3Values shown are those obtained for the nuc target in the samples that gave a SA POS, MRSA NEG result Calculated for the Specimen Processing Control of the samples that gave a SA NEG, MRSA NEG result

# Sample Storage

Specimens can be stored at25 $\pm 2 ^ { \circ } \complement$ for a maximum of 48 hours or at $2 . 8 \cdot C$ for a maximum of 120 hours (5 days) before testing. In case of repeat testing from the Sample Buffer Tube, the following storage conditions apply:

within 36 hours of the steps covered in the Specimen Preparation section of the package insert, when stored at $2 5 \pm 2 ^ { \circ } C$ or up to 120h (5 days) after the end of the initial run when stored at $2 . 8 ^ { \circ } C$ .

# Controls

External Control materials are not provided by BD. Various types of External Controls are recommended to allow the user to select the most appropriate for their laboratory quality control program:

Commercially available control materials [e.g. a reference MRSA strain (ATCC 43300), and Methicillin-susceptible Staphylococcus aureus strain (e.g. ATCC 291) can be used as positive controls. Staphylococcus epidermidis strain (e.g. ATCC 12228) can be used as negative control.].

# 8D Diagnostics BD MAX ™ StaphSR Assay PreMarket Notification

Previously characterized specimiens known to be positive or negative for S.   
aureus or MRSA.

The assay includes a Sample Processing Control (SPC) that is present in the Extraction Tube. The SPC monitors DNA extraction steps, thermal cycling steps, reagent integrity and the presence of inhibitory substances.

# Analytical Sensitivity

The analytical sensitivity (Limit of Detection or LoD) for the BD MAX ™ StaphSR assay was determined as follows: positive specimens were prepared by soaking swabs in a wide range of MRSA or MSSA bacterial suspensions prepared and quantified from cultures. The tested strains included 11 MRSA strains representing 11 MREJ genotypes (i, i, i, iv, v, vi, vii, i, ii, xiv and xxi) corresponding to 5 SCCmec types (I, II, II, IV and XI) as well as 2 MSSA strains. The swabs were then eluted in simulated nasal matrix. Each MRSA and MSSA strain was tested in replicates of 24 per concentration by 2 different operators using 3 different production lots of the BD MAX™ StaphSR assay. Analytical sensitivity (LoD), defined as the lowest concentration at which at least $9 5 \%$ of all replicates tested positive, ranged from 64 to 343 CFU/swab (Table 5) for the detection of MRSA strains and from 174 to 211 CFU/swab (Table 6) for the detection of MSSA strains.

Table 5: Limit of Detection of MRSA Genotypes by the BD MAX ™ StaphSR Assay   

<table><tr><td rowspan=1 colspan=1>MRSA Strainf</td><td rowspan=1 colspan=1>MREJ Genotype-) . .</td><td rowspan=1 colspan=1>SCCmec type</td><td rowspan=1 colspan=1>LoD Concentration[CFU/swab (95% C12)]</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Type i</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>84 (49. 142)</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Type ii</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>103 (64,167)</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Type iii</td><td rowspan=1 colspan=1>III</td><td rowspan=1 colspan=1>160 (93, 278</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Type iv</td><td rowspan=1 colspan=1>III</td><td rowspan=1 colspan=1>68 (42,109)</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Type v</td><td rowspan=1 colspan=1>IV</td><td rowspan=1 colspan=1>128 (73,225)</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Type vi</td><td rowspan=1 colspan=1>ND^f}$</td><td rowspan=1 colspan=1>343 (186.632)</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Type vii</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>219(110,439)</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>Type ix</td><td rowspan=1 colspan=1>ND^}$</td><td rowspan=1 colspan=1>144 (82,255)</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>Type xiii</td><td rowspan=1 colspan=1>ND^{}$</td><td rowspan=1 colspan=1>64 (36.114)</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Type xiv</td><td rowspan=1 colspan=1>$ND^}$</td><td rowspan=1 colspan=1>78 (48,127)</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>Type xxi4</td><td rowspan=1 colspan=1>XI</td><td rowspan=1 colspan=1>112 (64, 197)</td></tr></table>

Cmec type does not correlate to the MREJ type as these are two different typing methods. Confidence Intervals $\mathfrak { s } _ { \mathsf { N D } } =$ not determined mecC-containing MRSA strains (Also known as mecALGA2s, strain)

Table 6: Limit of Detection of MSSA by the BD MAX™ StaphSR Assay   

<table><tr><td rowspan=1 colspan=1>MSSA Strain</td><td rowspan=1 colspan=1>LoD Concentration [CFU/swab(95% C1)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>174 (89,341</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>211 (105, 428)</td></tr></table>

1Cl: Confidence Intervals

# Analytical Inclusivity

An analytical inclusivity study was performed using a variety of MRSA and MSSA strains, taking into account geographic origin, MREJ genotype (wild type and mutant), SCCmec type, Pulsed-Field Gel Electrophoresis (PFGE) type, temporal diversity and susceptibility pattern. Seventy-seven (77) MRSA strains from 27 countries (see Table 7) and 51 MSSA strains from 16 countries were tested in this study, including strains

# BD Diagnostics BD MAX™M StaphSR Assay PreMarket Notification

from public collections and from well-characterized clinical isolates, including Vancomycin-Resistant Staphylococcus aureus (VRSA) and Vancomycin Intermediate Staphylococcus aureus (VISA) strains.

The BD MAX™ StaphSR assay detected MREJ types i, ii, ii, iv, v, vi, vii, ix, xii, xiv and xxi when tested at low bacterial load (2-3 x LoD). The BD MAX ™ StaphSR assay detected MRSA SCCmec types 1, II, II, IV, V, VI, VII, VII and XI as well as MRSA PFGE types USA 100 to 800, 1000 and 1100 at 2-3 x LoD. All MRSA strains displaying additional resistance to vancomycin (VRSA and VISA) were also detected. The BD MAX™M StaphSR assay detected all 51 MSSA strains tested including mecA empty cassette variants.

Table 7: MRSA Strains Tested in the Inclusivity Study of the BD MAX™ StaphSR Assay.   

<table><tr><td rowspan=1 colspan=1>Collection*:&quot;.e.</td><td rowspan=1 colspan=1>Reference.Number&#x27;i:1</td><td rowspan=1 colspan=1>MREJType .&quot;</td><td rowspan=1 colspan=1>SCCmectyping / PFGEtype.&#x27; &quot;</td></tr><tr><td rowspan=8 colspan=1>ATCC</td><td rowspan=1 colspan=1>ATCC BAA-1770</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>USA1000</td></tr><tr><td rowspan=1 colspan=1>ATCC BAA-421</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>VI</td></tr><tr><td rowspan=1 colspan=1>ATCC BAA-38</td><td rowspan=1 colspan=1>i</td><td rowspan=1 colspan=1>t</td></tr><tr><td rowspan=1 colspan=1>ATCC BAA-41</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>II</td></tr><tr><td rowspan=1 colspan=1>ATCC BAA-39</td><td rowspan=1 colspan=1>iii</td><td rowspan=1 colspan=1>IlI</td></tr><tr><td rowspan=1 colspan=1>ATCC BAA-40</td><td rowspan=1 colspan=1>iv</td><td rowspan=1 colspan=1>III</td></tr><tr><td rowspan=1 colspan=1>ATCC 43300</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>II</td></tr><tr><td rowspan=1 colspan=1>ATCC 33592</td><td rowspan=1 colspan=1>iv</td><td rowspan=1 colspan=1>III</td></tr><tr><td rowspan=4 colspan=1>Harmonycollection ofEuropeanepidemicMRSA</td><td rowspan=1 colspan=1>62305</td><td rowspan=1 colspan=1>ii mut36</td><td rowspan=1 colspan=1>IV</td></tr><tr><td rowspan=1 colspan=1>97S99</td><td rowspan=1 colspan=1>ii mut45</td><td rowspan=1 colspan=1>IV</td></tr><tr><td rowspan=1 colspan=1>3717</td><td rowspan=1 colspan=1>iiii</td><td rowspan=1 colspan=1>III</td></tr><tr><td rowspan=1 colspan=1>9805-01937</td><td rowspan=1 colspan=1>iii mut45</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=2 colspan=1>LSPQ</td><td rowspan=1 colspan=1>ID-61882</td><td rowspan=1 colspan=1>iii</td><td rowspan=1 colspan=1>III / CMRSA-3</td></tr><tr><td rowspan=1 colspan=1>ID-61880</td><td rowspan=1 colspan=1>vii</td><td rowspan=1 colspan=1>II / CMRSA-1</td></tr><tr><td rowspan=17 colspan=1>NARSA</td><td rowspan=1 colspan=1>NRS383</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>II / USA200</td></tr><tr><td rowspan=1 colspan=1>NRS385</td><td rowspan=1 colspan=1>i</td><td rowspan=1 colspan=1>IV / USA500</td></tr><tr><td rowspan=1 colspan=1>NRS715</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>II/USA600</td></tr><tr><td rowspan=1 colspan=1>NRS386</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>IV / USA700</td></tr><tr><td rowspan=1 colspan=1>NRS686</td><td rowspan=1 colspan=1>i</td><td rowspan=1 colspan=1>IV/IBERIAN</td></tr><tr><td rowspan=1 colspan=1>NRS23</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>II</td></tr><tr><td rowspan=1 colspan=1>VRS5^{3</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>NRS1</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>lI</td></tr><tr><td rowspan=1 colspan=1>NRS4*</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>II</td></tr><tr><td rowspan=1 colspan=1>VRS2^3</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>VRS41.3</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>NRS382</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>II / USA100</td></tr><tr><td rowspan=1 colspan=1>NRS384</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>IV / USA300</td></tr><tr><td rowspan=1 colspan=1>NRS387</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>IV / USA800</td></tr><tr><td rowspan=1 colspan=1>NRS484</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>IV / USA1100</td></tr><tr><td rowspan=1 colspan=1>NRS645</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>IV/IBERIAN</td></tr><tr><td rowspan=1 colspan=1>NRS123</td><td rowspan=1 colspan=1>ii mut36</td><td rowspan=1 colspan=1>IV / USA400</td></tr><tr><td rowspan=3 colspan=1>NA</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>II / USA 100</td></tr><tr><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>iii</td><td rowspan=1 colspan=1>I1 / USA 100</td></tr><tr><td rowspan=1 colspan=1>5599</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>II / USA100</td></tr></table>

# BD Diagnostics BD MAX™ StaphSR Assay PreMarket Notification

<table><tr><td rowspan=1 colspan=1>Collection&#x27; :</td><td rowspan=1 colspan=1>Number</td><td rowspan=1 colspan=1>.! Type.</td><td rowspan=1 colspan=1>SCCmectyping/ PFGEtype</td></tr><tr><td rowspan=43 colspan=1></td><td rowspan=1 colspan=1>7909</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>IV / USA300</td></tr><tr><td rowspan=1 colspan=1>7916</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>IV / USA300</td></tr><tr><td rowspan=1 colspan=1>7917</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>IV / USA300</td></tr><tr><td rowspan=1 colspan=1>7921</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>IV / USA300</td></tr><tr><td rowspan=1 colspan=1>7922</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>IV / USA300</td></tr><tr><td rowspan=1 colspan=1>7913</td><td rowspan=1 colspan=1>ii mut36</td><td rowspan=1 colspan=1>IV / USA400</td></tr><tr><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>ji</td><td rowspan=1 colspan=1>IV / USA 800</td></tr><tr><td rowspan=1 colspan=1>1555$</td><td rowspan=1 colspan=1>xxi</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>MAH 30$</td><td rowspan=1 colspan=1>xxi</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>CCRI-11840</td><td rowspan=1 colspan=1>i</td><td rowspan=1 colspan=1>VIII</td></tr><tr><td rowspan=1 colspan=1>JCSC6082</td><td rowspan=1 colspan=1>iii</td><td rowspan=1 colspan=1>VII</td></tr><tr><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>xiii</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>5109</td><td rowspan=1 colspan=1>xiv</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>CCRI-12480</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>CCRI-12496</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>CCRI-12640 2</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>CCRI-9866 2</td><td rowspan=1 colspan=1>ii mut36</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>iii</td><td rowspan=1 colspan=1>V</td></tr><tr><td rowspan=1 colspan=1>347101</td><td rowspan=1 colspan=1>iii</td><td rowspan=1 colspan=1>V</td></tr><tr><td rowspan=1 colspan=1>CCRi-12503</td><td rowspan=1 colspan=1>ii</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>CCRI-12790</td><td rowspan=1 colspan=1>iiI</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>CCRI-12608</td><td rowspan=1 colspan=1>iv</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>CCRI-8895</td><td rowspan=1 colspan=1>iv</td><td rowspan=1 colspan=1>II</td></tr><tr><td rowspan=1 colspan=1>CCRI-1263(R523)</td><td rowspan=1 colspan=1>V</td><td rowspan=1 colspan=1>IV</td></tr><tr><td rowspan=1 colspan=1>CCRI-12767</td><td rowspan=1 colspan=1>v</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>571</td><td rowspan=1 colspan=1>vi</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>MLST 22 HOS47.3.270206 MJS</td><td rowspan=1 colspan=1>vi</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>CCRI-12425 2</td><td rowspan=1 colspan=1>vii</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>CCRI-12763</td><td rowspan=1 colspan=1>vii</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>CCRI-9583</td><td rowspan=1 colspan=1>vii</td><td rowspan=1 colspan=1>Ⅱ</td></tr><tr><td rowspan=1 colspan=1>CCRI-9711</td><td rowspan=1 colspan=1>vii</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>521</td><td rowspan=1 colspan=1>vi</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>CCRI-9681</td><td rowspan=1 colspan=1>ix</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>494</td><td rowspan=1 colspan=1>xii</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>ST2011 11005</td><td rowspan=1 colspan=1>xxi</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>126</td><td rowspan=1 colspan=1>xiv</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>CCRI-8894</td><td rowspan=1 colspan=1>i</td><td rowspan=1 colspan=1>I</td></tr><tr><td rowspan=1 colspan=1>MAH 20$</td><td rowspan=1 colspan=1>xxi</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>MAH 1$}$</td><td rowspan=1 colspan=1>xxi</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>CCRI-1262</td><td rowspan=1 colspan=1>iiii</td><td rowspan=1 colspan=1>III</td></tr><tr><td rowspan=1 colspan=1>CCRI-2025</td><td rowspan=1 colspan=1>V</td><td rowspan=1 colspan=1>IV</td></tr><tr><td rowspan=1 colspan=1>CCRI-9773</td><td rowspan=1 colspan=1>vii</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>CCRI-9624</td><td rowspan=1 colspan=1>ii mut36</td><td rowspan=1 colspan=1>ND</td></tr></table>

'The initial result was negative for MRSA. Both samples (ATCC BAA42 and VRS4) were repeated from the SBT and assay results are conforming (SA+, MRSA+).

# BD Diagnostics BD MAX ™ StaphSR Assay PreMarket Notification

These are the results for the repeats as the initial run gave an IND result due to a PCR heater warning.   
3VRSA strains (http://www.narsa.net/control/member/repositories) VISA strains (http://www.narsa.net/control/member/repositories) mecC variant strains

# Evaluation of a Well Characterized Challenge Strain Panel

Anaditial analytical study wascaut evaluatehanalyical perforan of the BD MAX™ StaphSR assay using a well characterized challenge strain panel:

Seventeen (17) out of 17 MRSA strains with high and low oxacillin minimum inhibitory concentrations (MICs), including PFGE types USA 100 to 800, 1000, PFGE type IV/IBERIAN and mecC variant (mecA-containing S. aureus strain LGA251) tested at a concentration of $_ { 2 - 3 \times }$ LoD, exhibited SA POS, MRSA POS results. Four (4) out of 4 BORSA strains (Borderline Oxacillin-Resistant S. aureus) tested at ${ \geq } 1 0 ^ { 6 }$ CFU/swab, exhibited SA POS, MRSA NEG results. Five (5) out of 5 MSSA strains tested at $e 1 0 ^ { 6 }$ CFU/swab, exhibited SA POS, MRSA NEG results − One (1) out of 1 Methicillin-Resistant Staphylococcus epidermidis (MRSE) strains tested at $\geq 1 0 ^ { 6 }$ CFU/swab, exhibited a negative result (SA NEG, MRSA NEG).

# Analytical Specificity

The BD MAX ™ StaphSR assay was performed on samples containing high levels of non-target organisms and MSSA strains (Table 8), using the BD MAX™ System, to demonstrate the specificity of the assay for detection of MRSA and SA.

Fifteen (15) out of 15 empty cassette variant MSSA strains tested at $\geq 1 0 ^ { 6 }$ CFU/swab produced SA POS, MRSA NEG results. Fifty-seven (57) out of 57 strains of various non-staphylococcal species tested at a concentration of at least $e 1 0 ^ { \circ }$ CFU/mL (except for Cryptococcus neoformans which was tested at $\mathsf { 3 } \mathsf { x } 1 0 ^ { 5 }$ CFU/swab) produced negative results (SA NEG, MRSA NEG). Forty-five (45) Coagulase-Negative staphylococcal strains (CoNS) and Coagulase-Positive staphylococcal strains (CoPS) representing 28 species were tested at a concentration of 0.5 McFarland with the BD MAX ™M StaphSR assay. Forty-five (45) of the 45 strains tested exhibited negative results (SA NEG, MRSA NEG).   
Fifty (50) out of 50 MSSA strains tested at high concentrations $z 1 0 ^ { 6 }$ CFU/swab), produced SA POS, MRSA NEG results. Seventeen (17) viruses representing 12 different viral species were tested at $\geq$ $1 0 ^ { 5 }$ PFU/mL. All 17 viruses produced negative results (SA NEG, MRSA NEG).

# BD Diagnostics BD MAX ™ StaphSR Assay PreMarket Notification.

Table 8: Microorganisms Tested for the Analytical Specificity Study   

<table><tr><td rowspan=1 colspan=5>. I. : :       ?, Non-Staphylococcal Species</td></tr><tr><td rowspan=1 colspan=1>Acinetobaterbaumannii</td><td rowspan=1 colspan=1>Corynebacteriumbovis</td><td rowspan=1 colspan=1>Escherichia coli(3 strains)</td><td rowspan=1 colspan=1>Neisseriameningitidis</td><td rowspan=1 colspan=1>Pasteurellaaerogenes</td></tr><tr><td rowspan=1 colspan=1>Acinetobaterhaemolyticus</td><td rowspan=1 colspan=1>Corynebacteriumflavescens</td><td rowspan=1 colspan=1>Haemophilusinfluenzae</td><td rowspan=1 colspan=1>Streptococcusanginosus</td><td rowspan=1 colspan=1>Proteus mirabilis</td></tr><tr><td rowspan=1 colspan=1>Bacillus cereus</td><td rowspan=1 colspan=1>Corynebacteriumgenitalium</td><td rowspan=1 colspan=1>Klebsiella oxytoca</td><td rowspan=1 colspan=1>Streptococcusagalactiae</td><td rowspan=1 colspan=1>Proteus vulgaris</td></tr><tr><td rowspan=1 colspan=1>Bordetellapertussis</td><td rowspan=1 colspan=1>Cryptococcusneoformans</td><td rowspan=1 colspan=1>Klebsiellapneumoniae</td><td rowspan=1 colspan=1>Streptococcusmitis</td><td rowspan=1 colspan=1>Providencia stuartii</td></tr><tr><td rowspan=1 colspan=1>Candida albicans(2 strains)</td><td rowspan=1 colspan=1>Enterobacteraerogenes</td><td rowspan=1 colspan=1>Lactobacilluscrispatus</td><td rowspan=1 colspan=1>Streptococcusmutans</td><td rowspan=1 colspan=1>Pseudomonasaeruginosa</td></tr><tr><td rowspan=1 colspan=1>Candidaguilliermondii</td><td rowspan=1 colspan=1>Enterobactercloacae</td><td rowspan=1 colspan=1>Lactobacillusreuteri</td><td rowspan=1 colspan=1>Streptococcuspneumoniae</td><td rowspan=1 colspan=1>Pseudomonasfluorescens</td></tr><tr><td rowspan=1 colspan=1>Candida tropicalis</td><td rowspan=1 colspan=1>Enterococcusfaecalis</td><td rowspan=1 colspan=1>Lactobacillusacidophilus</td><td rowspan=1 colspan=1>Streptococcuspyogenes</td><td rowspan=1 colspan=1>Salmonellaenterica subsp.Enterica</td></tr><tr><td rowspan=1 colspan=1>Candida glabrata</td><td rowspan=1 colspan=1>Enterococcusfaecium</td><td rowspan=1 colspan=1>Listeriamonocytogenes</td><td rowspan=1 colspan=1>Streptococcussalivarius</td><td rowspan=1 colspan=1>Serratiamarcescens</td></tr><tr><td rowspan=1 colspan=1>Citrobacter freundii</td><td rowspan=1 colspan=1>Enterococcusflavescens</td><td rowspan=1 colspan=1>Micrococcus luteus</td><td rowspan=1 colspan=1>Streptococcussanguinis</td><td rowspan=1 colspan=1>Shigella sonnei</td></tr><tr><td rowspan=1 colspan=1>Citrobacter koseri</td><td rowspan=1 colspan=1>Enterococcus hirae</td><td rowspan=1 colspan=1>Moraxellacatarhalis</td><td rowspan=1 colspan=1>Streptococcus suis</td><td rowspan=1 colspan=1>Yersiniaenterocolitica</td></tr><tr><td rowspan=1 colspan=1>Corynebacteriumaquaticus</td><td rowspan=1 colspan=1>Enterrococcusgallinarum</td><td rowspan=1 colspan=1>Neisseriagonorrhoeae</td><td rowspan=1 colspan=1>Streptococcus sp.</td><td rowspan=1 colspan=1></td></tr></table>

![](images/f32dadd485ac20ca5754709873672bbabbc1275296460bb2b975edff66420554.jpg)

<table><tr><td rowspan=1 colspan=1>Staphylococcusintermedius</td><td rowspan=1 colspan=1>Staphylococcuslutrae (2 stains)</td><td rowspan=1 colspan=1>Staphylococcuspseudointermedius</td><td rowspan=1 colspan=1>Staphylococcusschleifer</td><td rowspan=1 colspan=1>Staphylococcusschleiferi subsp.coagulans</td></tr><tr><td rowspan=1 colspan=1>Staphylococcusdelphini</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

<table><tr><td rowspan=1 colspan=5>Various Coagulase Negative Staphylococcus Species&#x27; :*,</td></tr><tr><td rowspan=1 colspan=1>Staphylococcusarlettae</td><td rowspan=1 colspan=1>Staphylococcuschromogenes</td><td rowspan=1 colspan=1>Staphylococcusgallinarum</td><td rowspan=1 colspan=1>Staphylococcuslentus</td><td rowspan=1 colspan=1>Staphylococcussciuni</td></tr><tr><td rowspan=1 colspan=1>Staphylococcusauricularis</td><td rowspan=1 colspan=1>Staphylococcuscohnii subsp.urealyticum</td><td rowspan=1 colspan=1>Staphylococcushaemolyticus(3 strains)</td><td rowspan=1 colspan=1>Staphylococcuslugdunensis</td><td rowspan=1 colspan=1>Staphylococcussimulans</td></tr><tr><td rowspan=1 colspan=1>Staphylococcuscapitis</td><td rowspan=1 colspan=1>Staphylococcusepidermidis(9 strains)</td><td rowspan=1 colspan=1>Staphylococcushominis (3 strains)</td><td rowspan=1 colspan=1>Staphylococcuspasteuri</td><td rowspan=1 colspan=1>Staphylococcuswamen (2 strains)</td></tr><tr><td rowspan=1 colspan=1>Staphylococcuscaprae</td><td rowspan=1 colspan=1>Staphylococcusequorum.</td><td rowspan=1 colspan=1>Staphylococcushominis subsp.hominis</td><td rowspan=1 colspan=1>Staphylococcuspulvereri</td><td rowspan=1 colspan=1>Staphylococcusxylosus (2 strains)</td></tr><tr><td rowspan=1 colspan=1>Staphylococcuscamosus</td><td rowspan=1 colspan=1>Staphylococcusfelis</td><td rowspan=1 colspan=1>Staphylococcuskloosii</td><td rowspan=1 colspan=1>Staphylococcussaprophyticus</td><td rowspan=1 colspan=1>Staphylococcusxylosus</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Adenovirus(type 1 and 7A)</td><td rowspan=1 colspan=1>Enterovirus</td><td rowspan=1 colspan=1>Humanparainfluenza (type1.2.3</td><td rowspan=1 colspan=1>Measles</td><td rowspan=1 colspan=1>Respiratorysyncytial virus</td></tr><tr><td rowspan=1 colspan=1>Humancoronavirus (2)</td><td rowspan=1 colspan=1>Epstein Barr Virus</td><td rowspan=1 colspan=1>Humanmetapneumovirus</td><td rowspan=1 colspan=1>Mumps virus</td><td rowspan=1 colspan=1>Rhinovirus</td></tr><tr><td rowspan=1 colspan=1>Cytomegalovirus</td><td rowspan=1 colspan=1>Human influenzavirus (type A andB)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

# BD Diagnostics BD MAX™ StaphSR Assay PreMarket Notification

# Interfering Substances

Twenty nine (29) microorganisms and chemical substances occasionally used in the nares or found in nasal swab specimens were evaluated for potential interference with the BD MAX™ StaphSR assay (Table 9). MRSA negative samples and MRSA positive samples at 2-3 x LoD'were tested with the highest amount of each compound or microorganism likely to be found at the sampling site or on the nasal swab sample. Results demonstrated no reportable interference with any microorganisms or chemical substance except for Tobramycin that showed inhibition in the BD MAX™ StaphSR assay when tested at a concentration of $4 . 5 \times 1 0 ^ { - 3 }$ g/swab.

Table 9: Endogenous and Commercial Exogenous Substances Tested with the BD MAX™ StaphSR Assay   

<table><tr><td rowspan=1 colspan=1>*r     Substance&#x27;      &#x27; </td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>Mucin, from bovine submaxillary glands</td><td rowspan=1 colspan=1>NI</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Rhinocort aqua ™</td><td rowspan=1 colspan=1>Ni</td></tr><tr><td rowspan=1 colspan=1>Dexamethasone Sodium Phosphate OphtalmicSotutionUSP, 0.1% Dexamethasone Phosphate Equivalent</td><td rowspan=1 colspan=1>NI</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Zicam No-Drip Liquid ™ NasalGelTExtreme CongestionRelief</td><td rowspan=1 colspan=1>NI</td></tr><tr><td rowspan=1 colspan=1>Chloraseptic™</td><td rowspan=1 colspan=1>NI</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Fluticasone Propionate</td><td rowspan=1 colspan=1>NI</td></tr><tr><td rowspan=1 colspan=1>Taro-Mupirocin, Mupirocin Ointment USP, 2%</td><td rowspan=1 colspan=1>NI</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>LuffeelTM</td><td rowspan=1 colspan=1>NI</td></tr><tr><td rowspan=1 colspan=1>Long Lasting Dristan ™ Nasal Mist</td><td rowspan=1 colspan=1>NI</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Staphylococcus epidermidis</td><td rowspan=1 colspan=1>NI</td></tr><tr><td rowspan=1 colspan=1>Neo-Synephrine™</td><td rowspan=1 colspan=1>NI</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Micrococcus luteus</td><td rowspan=1 colspan=1>NI</td></tr><tr><td rowspan=1 colspan=1>Equate® Nasal Spray Decongestant</td><td rowspan=1 colspan=1>Ni</td><td></td><td></td><td rowspan=1 colspan=1>Enterococcus faecium</td><td rowspan=1 colspan=1>NI</td></tr><tr><td rowspan=1 colspan=1>Beconase AQ™</td><td rowspan=1 colspan=1>NI</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Enterococcus faecalis</td><td rowspan=1 colspan=1>NI</td></tr><tr><td rowspan=1 colspan=1>Flunisolide Nasal Solution USP, 0.025%</td><td rowspan=1 colspan=1>NI</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Escherichia coli</td><td rowspan=1 colspan=1>NI</td></tr><tr><td rowspan=1 colspan=1>Nasacort ™ AQ</td><td rowspan=1 colspan=1>NI</td><td rowspan=1 colspan=1>b</td><td></td><td rowspan=1 colspan=1>Corynebacterium flavescens</td><td rowspan=1 colspan=1>NI</td></tr><tr><td rowspan=1 colspan=1>Nasonex ™</td><td rowspan=1 colspan=1>NI</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Moraxella catarrhalis</td><td rowspan=1 colspan=1>NI</td></tr><tr><td rowspan=1 colspan=1>Relenza™</td><td rowspan=1 colspan=1>NI</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Staphylococcus hominis subsphominis</td><td rowspan=1 colspan=1>NI</td></tr><tr><td rowspan=1 colspan=1>Tobramycin</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Haemophilus influenzae</td><td rowspan=1 colspan=1>NI</td></tr><tr><td rowspan=1 colspan=1>Blood</td><td rowspan=1 colspan=1>NI</td><td rowspan=1 colspan=1></td><td></td><td rowspan=1 colspan=1>Streptococcus pneumoniae</td><td rowspan=1 colspan=1>NI</td></tr><tr><td rowspan=1 colspan=1>Flumist</td><td rowspan=1 colspan=1>NI</td><td rowspan=1 colspan=4></td></tr></table>

NI: No reportable interference with the BD MAX™" StaphSR assay. I: Reportable interference with the BD MAX ™ StaphSR assay.

# Microbial Competitive Inhibitory Effect

A study was conducted to determine the potential competitive inhibitory effect of:

an increasing concentration of MRSE when co-spiked with a low concentration $( 1 - 2 \times \mathsf { L o D } )$ of MRSA or MSSA, and   
an increasing concentration of MSSA when co-spiked with a low concentration $( 1 - 2 \times \mathsf { L o D } )$ of MRSA.

Results demonstrated competition from:

MRSE at an MRSA:MRSE ratio of $1 : \geq 1 \times 1 0 ^ { 3 }$ MRSE at an MSSA:MRSE ratio of $1 : 2 1 \times 1 0 ^ { 5 }$ MSSA at an MRSA:MSSA ratio of $1 : 2 1 \times 1 0 ^ { 4 }$

# Carryover / Cross-Contamination

A study was conducted to investigate the potential for carry-over/cross-contamination between high MRSA $( 2 1 0 ^ { 7 }$ CFU/swab) specimens and negative specimens throughout the BD MAX™ StaphSR workflow. Twelve (12) replicates of the high

# BD Diagnostics BD MAX ™ StaphSR Assay PreMarket Notification

positive sample and 12 replicates of the negative sample were tested in each run by alternating negative and positive replicates. Four (4) operators performed a total of 18 runs of 24 samples. Overall, from 203 reportable results out of 216 expected negative samples, 3 false positive results were obtained (3/203; $1 . 5 \% )$ due to carry-over contamination.

# Clinical Performance Studies

Clinical performance characteristics of the BD MAX™ StaphSR assay were determined in a multi-site prospective investigational study. Three (3) investigational centers participated in the study. To be enrolled in the study, patients had to be eligible for MRSA or SA testing according to institutional policies. Eligibility requirements for targeted screening as per clinical site policies included, but were not limited to: patients admitted into the particular healthcare system; patients admitted to the Intensive Care Unit; patients transferred to the Intensive Care Unit; pre-elective surgery patients; and patients being admitted from long-term care facilities. Specimens from patients previously enrolled in the study were excluded.

The Comparative Reference Method consisted of direct culture complemented by enriched culture. Enriched culture analysis was completed for all specimens that were negative for MRSA or SA by direct culture. Presumptive S. aureus colonies observed on selective (S. aureus) chromogenic medium were subcultured onto Blood Agar (BA). Identification was confirmed with an agglutination test, while methicillin resistance was confirmed by Cefoxitin disk $( 3 0 \ \mu \mathfrak { g } )$ diffusion susceptibility testing. Enrichment in Trypticase Soy Broth with $6 . 5 \%$ NaCi (TSB $6 . 5 \%$ NaCl) was completed in the event that MRSA or SA was not confirmed by the initial direct culture method. Turbid TSB $6 . 5 \%$ NaCl broth was used to inoculate additional chromogenic medium and BA plates; MRSA confirmation was performed as described above.

Results Obtained with the BD MAX™ StaphSR Assay in Comparison to the Reference Method

A total of 2451 specimens were enrolled in the study. Of those, 94 specimens were regarded as noncompliant per protocol criteria and three (3) fully compliant specimens gave final non-reportable PCR results. A total of 2354 specimen results were used to determine the clinical performance of the BD MAX™M StaphSR assay in comparison to the Reference Method (Tables 10 to 13).

Compared to the Reference Method (Direct/Enriched Culture), the BD MAX ™ StaphSR assay identified $9 3 . 1 \%$ of the MRSA positive specimens and $9 7 . 5 \%$ of the MRSA negative specimens (Table 10). For the population tested, this resulted in a Negative Predictive Value (NPV) of $9 9 . 5 \%$ and a Positive Predictive Value (PPV) of $7 3 . 2 \%$ .

# BD Diagnostics BD MAX ™ StaphSR Assay PreMarket Notification

Table 10: Results Obtained for MRSA with the BD MAX TM StaphSR Assay in Comparison to the Reference Method   

<table><tr><td rowspan=2 colspan=1>AllSites</td><td rowspan=1 colspan=4>.  Reference Method     *4</td></tr><tr><td rowspan=1 colspan=1>MRSA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>BD MAX™ StaphSR Assay</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>149</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>203</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>2140</td><td rowspan=1 colspan=1>2151</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>2194</td><td rowspan=1 colspan=1>2354</td></tr><tr><td rowspan=1 colspan=5>Sensitivity: 93.1% (149/160) (95% Cl: 88.1%, 96.1%)Specificity: 97.5% (2140/2194) (95% Cl:96.8%, 98.1%)PPV: 73.2% (95% CI: 67.8%, 78.3%)NPV: 99.5% (95% Cl: 99.1%, 99.7%)</td></tr></table>

'Further investigation was performed on specimens with discordant results between the Reference Method and the BD MAX ™ StaphSR assay. 12 of 54 MRSA False Positive BD MAX ™ StaphSR specimens were also found to be positive after repeat of Reference Method 5 of 11 MRSA False Negative BD MAX ™ StaphSR specimens were also found to be negative after repeat of Reference Method

Table 11: Site-by-Site Performance Obtained for MRSA with the BD MAX™M StaphSR Assay in Comparison to the Reference Method   

<table><tr><td rowspan=1 colspan=1>Clinical Sites</td><td rowspan=1 colspan=1> Prevalence</td><td rowspan=1 colspan=1>Sensitivity (95% Cl)&quot;</td><td rowspan=1 colspan=1>Specificity(95% Cl)</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>4.3% (41/960)</td><td rowspan=1 colspan=1>92.7% (38/41)(80.6%, 97.5%)</td><td rowspan=1 colspan=1>98.9% (908/918)(98.0%, 99.4%)</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>5.8% (38/650)</td><td rowspan=1 colspan=1>86.8% (33/38)(72.7%, 94.2%)</td><td rowspan=1 colspan=1>98.5% (583/592)(97.1%, 99.2%)</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>10.6% (81/765)</td><td rowspan=1 colspan=1>96.3% (78/81)(89.7%, 98.7%)</td><td rowspan=1 colspan=1>94.9% (649/684)(93.0%, 96.3%)</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>6.7% (160/2375 )</td><td rowspan=1 colspan=1>93.1% (149/160)(88.1%, 96.1%)</td><td rowspan=1 colspan=1>97.5% (2140/2194)(96.8%, 98.1%)</td></tr></table>

Prevalence based on reference method only Confidence interval 2375 specimens were reference method compliant

Compared to the Reference Method (Direct/Enriched Culture), the BD MAX™ StaphSR assay identified $9 2 . 0 \%$ of the SA positive specimens and $9 3 . 1 \%$ of the SA negative specimens (Tables 12 and 13). For the population tested, this resulted in a NPV of $9 6 . 8 \%$ and a PPV of $8 3 . 4 \%$ .

Table 12: Results Obtained for SA with the BD MAXT StaphSR Assay in Comparison to the Reference Method   

<table><tr><td rowspan=2 colspan=1>.&#x27;  14         All Sites &quot;-                        ${{$</td><td rowspan=1 colspan=4>&quot;     ,Reference Method:&quot;</td></tr><tr><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>BD MAX™ StaphSR Assay</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>599</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>717</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>1585</td><td rowspan=1 colspan=1>1637</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>651</td><td rowspan=1 colspan=1>1703</td><td rowspan=1 colspan=1>2354</td></tr><tr><td rowspan=1 colspan=5>Sensitivity: 92.0% (599/651) (95% Cl: 89.7%, 93.9%)Specificity: 93.1% (1585/1703) (95% Cl: 91.8%, 94.2%)PPV: 83.4% (95% CI: 81.9%, 85.8%)NPV: 96.8% (95% CI: 96.0%, 97.6%)</td></tr></table>

'Further investigation was performed on specimens with discordant results between the Reference Method and the BD MAX™ StaphSR assay. . 28 of 118 SA False Positive BD MAX™ StaphSR specimens were also found to be positive after repeat of Reference Method 23 of 52 SA False Negative BD MAX™ StaphSR specimens were also found to be negative after repeat of Reference Method

# BD Diagnostics BD MAX ™M StaphSR Assay PreMarket Notification

Table 13: Site-by-Site Performance Obtained for SA with the BD MAX ™ StaphSR Assay in Comparison to the Reference Method   

<table><tr><td rowspan=1 colspan=1>Clinical Sites</td><td rowspan=1 colspan=1>PPrevalence</td><td rowspan=1 colspan=1>Sensitivity.with:95% CI,</td><td rowspan=1 colspan=1>Specificity with 95% Cl</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>27.2% (261/960)</td><td rowspan=1 colspan=1>90.0% (235/261)(85.8%, 93.1%)</td><td rowspan=1 colspan=1>96.3% (672/698)(94.6%, 97.4%)</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>27.5% (179/650)</td><td rowspan=1 colspan=1>91.5% (162/177)(86.5%, 94.8%)</td><td rowspan=1 colspan=1>90.9% (412/453)(88.0%, 93.3%)</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>27.8% (213/765)</td><td rowspan=1 colspan=1>94.8% (202/213)(91.0%, 97.1%)</td><td rowspan=1 colspan=1>90.8% (501/552)(88.1%, 92.9%)</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>27.5% (653/2375 )</td><td rowspan=1 colspan=1>92.0% (599/561)(89.7%, 93.9%)</td><td rowspan=1 colspan=1>93.1% (1585/1703)(91.8%, 94.2%)</td></tr></table>

a Prevalence based on reference method only Confidence interval 2375 specimens were reference method compliant

# Results Obtained with the BD MAX™ StaphSR Assay in Comparison to Direct Culture

A total of 2451 specimens were enrolled in the study. Of those, 54 specimens were regarded as noncompliant per protocol criteria and four (4) fully compliant specimens gave non reportable PCR results. A total of 2393 specimen results were used to determine the positive and negative percent agreement of the BD MAX™ StaphSR assay in comparison to Direct Culture (Tables 14 to 17).

Compared to Direct Culture, the BD MAX™ StaphSR assay identified $9 6 . 5 \%$ of the MRSA positive specimens and $9 6 . 9 \%$ of the MRSA negative specimens (Tables 14 and 15).

Table 14: Results Obtained for MRSA with the BD MAX™M StaphSR Assay in Comparison to Direct Culture   

<table><tr><td rowspan=2 colspan=2>All Sites</td><td rowspan=1 colspan=3>F•   *7  Direct Culture</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>BD MAX™ StaphSR Assay</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>137</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>206</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>2182</td><td rowspan=1 colspan=1>2187</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>2251</td><td rowspan=1 colspan=1>2393</td></tr><tr><td rowspan=1 colspan=5>Positive Percent Agreement: 96.5% (137/142) (95% Cl: 92.0%, 98.5%)Negative Percent Agreement: 96.9% (2182/2251) (95% Cl: 96.1%, 97.6%)</td></tr></table>

Table 15: Site-by-Site Performance Obtained for MRSA with the BD MAX™ StaphSR Assay in Comparison to Direct Culture   

<table><tr><td rowspan=1 colspan=1>Clinical Sites:</td><td rowspan=1 colspan=1>Positive PercentAgreement with 95%C1:}$</td><td rowspan=1 colspan=1>Negative PercentAgreement with 95%CIa</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>100% (35/35)(90.1%, 100%)</td><td rowspan=1 colspan=1>98.6% (911/924)(97.6%, 99.2%)</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>93.5% (29/31)(79.3%, 98.2%)</td><td rowspan=1 colspan=1>97.8% (586/599)(96.3%, 98.7%)</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>96.1% (73/76)(89.0%, 98.6%)</td><td rowspan=1 colspan=1>94.1% (685/728)(92.1%, 95.6%)</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>96.5% (137/142)(92.0%, 98.5%)</td><td rowspan=1 colspan=1>96.9% (2182/2251)(96.1%, 97.6%)</td></tr></table>

Confidence interval

# BD Diagnostics BD MAX™ StaphSR Assay PreMarket Notification

Compared to Direct Culture, the BD MAX T StaphSR assay identified $9 5 . 1 \%$ of the SA positive specimens and $90 . 9 \%$ of the SA negative specimens (Tables 16 and 17).

Table 16: Results Obtained for SA with the BD MAXTM StaphSR Assay in Comparison to Direct Culture   

<table><tr><td rowspan=2 colspan=2>J&#x27;-All Sites                  i2.0..(1: .</td><td rowspan=1 colspan=3>1I  Direct Culturej.i</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>BD MAX™ StaphSR Assay</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>564</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>728</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>·1636</td><td rowspan=1 colspan=1>1665</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>593</td><td rowspan=1 colspan=1>1800</td><td rowspan=1 colspan=1>2393</td></tr><tr><td rowspan=1 colspan=5>Positive Percent Agreement: 95.1% (564/593) (95% Cl: 93.1%, 96.6%)Negative Percent Agreement: 90.9% (1636/1800) (95% Cl: 89.5%, 92.1%)</td></tr></table>

Table 17: Site-by-Site Performance Obtained for SA with the BD MAX™ StaphSR Assay in Comparison to Direct Culture   

<table><tr><td rowspan=1 colspan=1>ClinicalSites</td><td rowspan=1 colspan=1>Positive&#x27;PercentAgreement with95% CI</td><td rowspan=1 colspan=1>Negative&#x27;PercentAgreement with.95%CI</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>93.0% (213/229)(89.0%, 95.7%)</td><td rowspan=1 colspan=1>93.4% (682/730)(91.4%, 95.0%)</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>94.9% (149/157)(90.3%, 97.4%)</td><td rowspan=1 colspan=1>88.6% (419/473)(85.4%, 91.1%)</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>97.6% (202/207)(94.5%, 99.0%)</td><td rowspan=1 colspan=1>89.6% (535/597)(86.9, 91.8%)</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>95.1% (564/593)(93.1%, 96.6%)</td><td rowspan=1 colspan=1>90.9% (1636/1800)(89.5%, 92.1%)</td></tr></table>

Confidence interval

Out of 2399 nasal swab specimens tested with the BD MAX ™m StaphSR assay that were compliant at the specimen and PCR level, 15 $( 0 . 6 \% )$ were reported as Unresolved after initial testing. The Unresolved Rate after repeat testing is $0 . 0 4 \%$ (1/2399) (Table 18).

Table 18: Unresolved Rates   

<table><tr><td>Initial Unresolved Rates $h &quot;i</td><td>Unresolved Rates After:Repeat &quot;.y&#x27; i</td></tr><tr><td>0.6% (15/2399)* (95% Cl: 0.4%, 1.0%)</td><td>0.04% (1/2399) (95% CI: 0%, 0.2%)</td></tr></table>

Total number based on compliant specimens and BD MAX ™ StaphSR assay results

Out of the same 2399 nasal swab specimens tested with the BD MAX ™ StaphSR assay, 14 $( 0 . 6 \% )$ were initially reported as Indeterminate. No result remained Indeterminate upon repeat (two specimens were not retested). Eight (8) $( 0 . 3 \% )$ were initially reported as Incomplete. No result remained Incomplete upon repeat (one specimen was not retested).

# Empty Cassette Variants

Among the 2354 eligible specimens included in the clinical performance determination, a total of 10 specimens fit the empty cassette profile resulting in detection of MREJ, without mecA or mecC gene detection. All of the 10 specimens were verified true negative MRSA and true positive SA relative to the Reference Method.

# BD Diagnostics BD MAX ™ StaphSR Assay PreMarket Notification

# Expected Values

In the BD MAX™ StaphSR assay clinical study a total of 2395 reportable results, from specimens compliant at the specimen and PCR levels, were obtained from 3 geographically diverse sites and compared with Direct and Enriched culture. The study population was grouped into in-patient, out-patient and unknown categories. The number and percentage of positive cases, as determined by the BD MAX™ StaphSR assay, are presented in the table below:

<table><tr><td rowspan=1 colspan=1>i.J</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=2>BD MAXStaphSR Assay</td><td rowspan=2 colspan=1>PositivetMRSAPercentage</td><td rowspan=2 colspan=1>t&quot;Positive SAPercentage</td></tr><tr><td rowspan=1 colspan=1>1Group</td><td rowspan=1 colspan=1>Total NumberofSpecimens</td><td rowspan=1 colspan=1>Number of.MRSAPositive</td><td rowspan=1 colspan=1>Number of SAPositive   5</td></tr><tr><td rowspan=1 colspan=1>In-patient</td><td rowspan=1 colspan=1>1685</td><td rowspan=1 colspan=1>178</td><td rowspan=1 colspan=1>548</td><td rowspan=1 colspan=1>10.6%(178/1685)</td><td rowspan=1 colspan=1>32.5%(548/1685)</td></tr><tr><td rowspan=1 colspan=1>Out-patient</td><td rowspan=1 colspan=1>710</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>182</td><td rowspan=1 colspan=1>3.9%(28/710)</td><td rowspan=1 colspan=1>25.6%(182/710)</td></tr><tr><td rowspan=1 colspan=1>Total1</td><td rowspan=1 colspan=1>2395</td><td rowspan=1 colspan=1>206</td><td rowspan=1 colspan=1>730</td><td rowspan=1 colspan=1>8.6%(206/2395)</td><td rowspan=1 colspan=1>30.5%(730/2395)</td></tr></table>

Total specimens based on compliant PCR results.

GENEOHM SCIENCE CANADA, INC. (BD DIAGNOSTICS)   
PATRICIA DIONNE, PH.D, MBA   
DIRECTOR. REGULATORY AFFAIRS   
2555 BOUL. DU PARC-TECHNOLOGIQUE   
QUEBEC, QUEBEC, G1P 4S5   
CANADA

Re: K132822 Trade/Device Name: BD MAXTM StaphSR Regulation Number: 21 CFR 866.1640 Regulation Name: Antimicrobial Susceptibility Test Powder Regulatory Class: II Product Code: NQX. OOI Dated: September 16. 2013 Received: September 17, 2013

Dear Dr. Dionne:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enaciment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarkct approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The l contos prvisins hAc inc ients anal istraton st devices. good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH docs not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class I1 (Special Controls) or class I1 (PMA). it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21, Parts 800 to 898. In addition. FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including. but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809): medical device reporting (reporting of medical device-related adverse events) (21 CFR 803): good manufacturing practice requiremenis as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable. the electronic product radiation control provisions (Sections 531-542 of the Act): 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809). please contact the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDeviccs/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part .Fo       n ha CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarkel Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consumer Assistance at its tol-free number (800) 638-2041 or (301) 796-7100 or at its Internel address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/dcfault.hum.

Sincerely yours.

# Sally A. Hojvat -S

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostics and Radiological Health   
Center for Devices and Radiological Health

Enclosure

Indications for Use (Describe)

Te As  A uaiv AX R susceptibility testing.